CCM
ADMA icon

Catalio Capital Management’s ADMA Biologics ADMA Stock Holding History

Catalio Capital Management’s Portfolio ADMA Stock Details ADMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-564,461
Closed -$10.3M – 43
2025
Q4 		$10.3M Sell
564,461
-120,047
-18% -$2.02M 1.82% 23
2025
Q3 		$10M Buy
684,508
+114,804
+20% +$1.97M 1.86% 22
2025
Q2 		$10.4M Buy
+569,704
New +$11.6M 2.18% 17
2025
Q1 		– Sell
-512,724
Closed -$8.79M – 38
2024
Q4 		$8.79M Buy
+512,724
New +$9.65M 1.92% 20

Other funds holding ADMA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Catalio Capital Management's ADMA Position: Q1 2026 in Review

Catalio Capital Management sold out of ADMA Biologics (ADMA) in Q1 2026, closing a stake of 564,461 shares — an estimated $10.3M sold.

Catalio Capital Management first reported a position in ADMA in Q4 2024 and held it in 4 quarters. The position peaked at $10.4M in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.

  • Catalio Capital Management reported no remaining ADMA Biologics position as of Q1 2026 after selling out during the quarter.
  • Catalio Capital Management sold 564,461 ADMA Biologics shares in Q1 2026, an estimated $10.3M.
  • Catalio Capital Management first reported a position in ADMA Biologics in Q4 2024 and held it in 4 quarters.
  • Catalio Capital Management's ADMA Biologics position peaked at $10.4M in Q2 2025.
  • 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.

Based on Catalio Capital Management's 13F filing for Q1 2026, filed 15 May 2026.